Establishment and external validation of a prognostic model for predicting disease-free survival and risk stratification in breast cancer patients treated with neoadjuvant chemotherapy

References

• ChenWZhengRZengHZhangSThe updated incidences and mortalities of major cancers in China, 2011Chin J Cancer2015341150250726370301
   PubMedGoogle Scholar
• SiegelRLMillerKDJemalACancer statistics, 2017CA Cancer J Clin201767173028055103
   PubMed Web of Science ®Google Scholar
• GolshanMCirrincioneCTSikovWMAlliance for Clinical Trials in OncologyImpact of neoadjuvant chemotherapy in stage II-III triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (alliance)Ann Surg20152623434439 discussion 438–43926222764
   PubMed Web of Science ®Google Scholar
• BearHDAndersonSBrownANational Surgical Adjuvant Breast and Bowel Project Protocol B-27The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27J Clin Oncol200321224165417414559892
   PubMed Web of Science ®Google Scholar
• CortazarPZhangLUntchMPathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisLancet2014384993816417224529560
   PubMed Web of Science ®Google Scholar
• AbrialSCPenault-LlorcaFDelvaRHigh prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancerBreast Cancer Res Treat200594325526316267618
   PubMed Web of Science ®Google Scholar
• von MinckwitzGUntchMNueschEImpact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trialsBreast Cancer Res Treat2011125114515621042932
   PubMed Web of Science ®Google Scholar
• MougalianSSSoulosPRKilleleaBKUse of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United StatesCancer2015121152544255225902916
   PubMed Web of Science ®Google Scholar
• HamyA-SLamG-TLaasELymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinomaBreast Cancer Res Treat2018169229530429374852
   PubMed Web of Science ®Google Scholar
• RouzierRPusztaiLDelalogeSNomograms to predict patho-logic complete response and metastasis-free survival after preoperative chemotherapy for breast cancerJ Clin Oncol200523338331833916293864
   PubMed Web of Science ®Google Scholar
• KeamBImSAParkSNomogram predicting clinical outcomes in breast cancer patients treated with neoadjuvant chemotherapyJ Cancer Res Clin Oncol201113791301130821717200
   PubMed Web of Science ®Google Scholar
• ColleoniMBagnardiVRotmenszNA risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancerAnn Oncol20092071178118419218304
   PubMed Web of Science ®Google Scholar
• BalachandranVPGonenMSmithJJDeMatteoRPNomo-grams in oncology: more than meets the eyeLancet Oncol2015164e173e18025846097
   PubMed Web of Science ®Google Scholar
• IasonosASchragDRajGVPanageasKSHow to build and interpret a nomogram for cancer prognosisJ Clin Oncol20082681364137018323559
   PubMed Web of Science ®Google Scholar
• LuCHLiuCTChangPHDevelop and validation a nomogram to predict the recurrent probability in patients with major salivary gland cancerJ Cancer20178122247225528819427
   PubMed Web of Science ®Google Scholar
• YangYZhangYJZhuYPrognostic nomogram for overall survival in previously untreated patients with extranodal NK/T-cell lymphoma, nasal-type: a multicenter studyLeukemia20152971571157725697894
   PubMed Web of Science ®Google Scholar
• LeeCKSimesRJBrownCA prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancerAnn Oncol201324493794323104722
   PubMed Web of Science ®Google Scholar
• HirabayashiSKosugiSIsobeYDevelopment and external validation of a nomogram for overall survival after curative resection in serosa-negative, locally advanced gastric cancerAnn Oncol20142561179118424669009
   PubMed Web of Science ®Google Scholar
• LiangWZhangLJiangGDevelopment and validation of a nomogram for predicting survival in patients with resected non-small-cell lung cancerJ Clin Oncol201533886186925624438
   PubMed Web of Science ®Google Scholar
• WangYLiJXiaYPrognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomyJ Clin Oncol20133191188119523358969
   PubMed Web of Science ®Google Scholar
• TangLQLiCFLiJEstablishment and validation of prognostic nomograms for endemic nasopharyngeal carcinomaJ Natl Cancer Inst20161081djv29126467665
   PubMedGoogle Scholar
• MazouniCPeintingerFWan-KauSResidual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcomeJ Clin Oncol200725192650265517602071
   PubMed Web of Science ®Google Scholar
• TadrosABYangWTKrishnamurthySIdentification of patients with documented pathologic complete response in the breast after neo-adjuvant chemotherapy for omission of axillary surgeryJAMA Surg2017152766567028423171
   PubMed Web of Science ®Google Scholar
• HammondMEHayesDFDowsettMAmerican Society of Clinical OncologyCollege of American PathologistsAmerican Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancerJ Clin Oncol201028162784279520404251
   PubMed Web of Science ®Google Scholar
• PerezEADueckACMcCulloughAEPredictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteriaJ Natl Cancer Inst2012104215916222138096
   PubMedGoogle Scholar
• WolffACHammondMESchwartzJNAmerican Society of Clinical Oncology/College of American PathologistsAmerican Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancerJ Clin Oncol200725111814517159189
   PubMed Web of Science ®Google Scholar
• GoldhirschAWoodWCCoatesASGelberRDThurlimannBSennHJStrategies for subtypes – dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2011Ann Oncol20112281736174721709140
   PubMed Web of Science ®Google Scholar
• SwisherSKVilaJTuckerSLLocoregional control according to breast cancer subtype and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast-conserving therapyAnn Surg Oncol201623374975626511263
   PubMed Web of Science ®Google Scholar
• HoussamiNMacaskillPvon MinckwitzGMarinovichMLMamou-nasEMeta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapyEur J Cancer201248183342335422766518
   PubMed Web of Science ®Google Scholar
• CampRLDolled-FilhartMRimmDLX-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimizationClin Cancer Res200410217252725915534099
   PubMed Web of Science ®Google Scholar
• AsselainBBarlowWBartlettJLong-term outcomes for neo-adjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trialsLancet Oncol2017191273929242041
   PubMed Web of Science ®Google Scholar
• ZhouPJiangYZHuXClinicopathological characteristics of patients with HER2-positive breast cancer and the efficacy of trastuzumab in the People’s Republic of ChinaOnco Targets Ther201692287229527143924
   PubMed Web of Science ®Google Scholar